Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can AI predict dangerous complications after aortic dissection repair?

NCT ID NCT07745309

Knowledge-focused Sponsor: Chang Shu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study aims to create a large national registry of patients with type B aortic dissection, a serious condition where the aorta tears. By collecting data from about 60 hospitals across China, researchers will build a digital platform to standardize care and track long-term outcomes. Using artificial intelligence, they hope to develop a risk prediction model that can warn doctors about potential complications like stroke, kidney failure, or aortic rupture. The goal is to improve the quality of care and reduce death rates by identifying high-risk patients earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Routine endovascular repair (TEVAR) as standard care
What this could lead to
If successful, this could lead to an AI-driven early warning system that helps doctors identify high-risk patients sooner, potentially reducing complications and deaths from type B aortic dissection.
What could go wrong
This is an observational study, so it cannot prove that any specific treatment works. The risk prediction model may not be accurate across all hospitals, and the large scale may introduce data quality issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,375 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients without any exclusion criteria who received treatment for Stanford type B aortic dissection at each participating center

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Aged between 18 and 80 years (inclusive); 2. Definite diagnosis of Stanford type B aortic dissection confirmed by three-dimensional CTA reconstruction; 3. Underwent TEVAR, including standalone TEVAR and hybrid procedures (only non-thoracotomy hybrid procedures); 4. Patients and their families signed informed consent and agreed to complete the 2-year full follow-up. Exclusion Criteria 1. Presence of severe comorbidities or other diseases (e.g., severe chronic obstructive pulmonary disease, malignant tumors, dementia) or any physical condition that may affect patient compliance with this study; 2. A previous history of thoracic aortic surgery (including TEVAR, hybrid surgery, and open surgery); 3. Congenital aortic malformations; 4. Requiring concurrent intervention for cardiac or aortic sinus root lesions, or cardiac diseases that would alter the postoperative medication regimen; 5. Pregnant or breastfeeding women; 6. Complicated with Stanford type A intramural hematoma, supra-aortic vessel occlusion, or refusal of relevant repair; 7. A history of stroke or acute myocardial infarction within 30 days prior to surgery; 8. Receipt of any major surgical or interventional procedures within 30 days prior to surgery; 9. Scheduled to undergo any major elective surgical or interventional procedures within 30 days after index surgery; 10. Participation in other ongoing drug or device trials with unmet primary study endpoints.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endovascular surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.